The choice of the intravenous fluid influences the tolerance of acute normovolemic anemia in anesthetized domestic pigs by Pape, Andreas et al.
RESEARCH Open Access
The choice of the intravenous fluid influences the
tolerance of acute normovolemic anemia in
anesthetized domestic pigs
Andreas Pape
1*, Saskia Kutschker
1, Harry Kertscho
1, Peter Stein
1, Oliver Horn
1, Mischa Lossen
1, Bernhard Zwissler
2
and Oliver Habler
3
Abstract
Introduction: The correction of hypovolemia with acellular fluids results in acute normovolemic anemia. Whether
the choice of the infusion fluid has an impact on the maintenance of oxygen (O2) supply during acute
normovolemic anemia has not been investigated so far.
Methods: Thirty-six anesthetized and mechanically ventilated pigs were hemodiluted to their physiological limit of
anemia tolerance, reflected by the individual critical hemoglobin concentration (Hbcrit). Hbcrit was defined as the
Hb-concentration corresponding with the onset of supply-dependency of total body O2-consumption (VO2). The
hemodilution protocol was randomly performed with either tetrastarch (6% HES 130/0.4, TS-group, n = 9), gelatin
(3.5% urea-crosslinked polygeline, GEL-group, n = 9), hetastarch (6% HES 450/0.7, HS-group, n = 9) or Ringer’s
solution (RS-group, n = 9). The primary endpoint was the dimension of Hbcrit, secondary endpoints were
parameters of central hemodynamics, O2 transport and tissue oxygenation.
Results: In each animal, normovolemia was maintained throughout the protocol. Hbcrit was met at 3.7 ± 0.6 g/dl
(RS), 3.0 ± 0.6 g/dl (HS P < 0.05 vs. RS), 2.7 ± 0.6 g/dl (GEL, P < 0.05 vs. RS) and 2.1 ± 0.4 g/dl (TS, P < 0.05 vs. GEL,
HS and RS). Hemodilution with RS resulted in a significant increase of extravascular lung water index (EVLWI) and a
decrease of arterial oxygen partial pressure (paO2), and O2 extraction ratio was increased, when animals of the TS-,
GEL- and HS-groups met their individual Hbcrit.
Conclusions: The choice of the intravenous fluid has an impact on the tolerance of acute normovolemic anemia
induced by acellular volume replacement. Third-generation tetrastarch preparations (e.g., HES 130/0.4) appear most
advantageous regarding maintenance of tissue oxygenation during progressive anemia. The underlying mechanism
includes a lower degree of extravasation and favourable effects on microcirculatory function.
Introduction
The correction of hypovolemia is an essential goal in the
treatment of critically ill patients. However, the use of
acellular fluids (that is, crystalloid or colloidal solutions)
results in the dilution of the circulating cell mass (acute
normovolemic anemia) with a corresponding decrease of
O2 transport capacity [1-3].
Acute normovolemic anemia is initially compensated
by increases of cardiac output and arterio-venous O2
extraction [4]. Moreover, O2 supply (DO2) physiologi-
cally exceeds O2 demand (reflected by total body O2
consumption (VO2) under resting conditions) by the
factor three to four. When DO2 begins to decrease at
lower Hb concentrations, the total body O2 demand is
still met, and VO2 remains constant despite decreasing
Hb concentrations (O2 supply-independency of VO2).
When DO2 falls below a critical value, the amount of
O2 delivered to the tissues becomes insufficient to meet
their O2 demand and VO2 starts to decline (O2 supply-
dependency of VO2) [5]. The corresponding critical
hemoglobin concentration (Hbcrit)r e p r e s e n t st h eu l t i -
mate limit of the individual anemia tolerance.
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varies considerably and different intravenous (IV) fluids
are used for volume replacement [6]. However, currently
available IV fluids differ in their pharmacodynamic and
kinetic profile (for example, molecular weight, plasma
half-life, volume expansion effect) and in their effects on
rheology and microcirculatory function.
We hypothesized that these properties might have an
influence on the tolerance of acute normovolemic ane-
mia. In this regard, the present study was conceived to
compare potential effects of four commonly used IV
fluids: low-molecular hydroxyethyl starch (HES) (tetra-
starch, 6% HES 130/0.4), high-molecular HES (hetas-
tarch, 6% HES 450/0.7), gelatin (3.5% urea-crosslinked
polygeline), and crystalloid volume replacement with
Ringer’s solution.
Materials and methods
After approval by the local governmental review board
(Regional Council Darmstadt, department for veterinary
affairs/V54), experiments were performed in 36 healthy
farm-bred pigs of either sex (body weight 24.0 ± 3.7 kg).
All animals received good care in compliance with the
Guide for the Care and Use of Laboratory Animals.
Anesthesia and ventilation
Animals were denied food 12 hours before each experi-
ment started, but had free access to water. After intra-
muscular premedication with 10 mg/kg ketamine
(Ketavet™, Parke-Davis, Berlin, Germany) and 1 mg/kg
midazolam (Midazolam™, Ratiopharm, Ulm, Germany),
anesthesia was induced by IV injection of 3 mg/kg pro-
pofol (Propofol™, Braun, Melsungen, Germany) and 30
μg/kg fentanyl (Fentanyl™, Janssen, Neuss, Germany)
and maintained by continuous infusion of propofol (0.16
mg/kg/min), midazolam (0.01 mg/kg/min) and fentanyl
(0.8 μg/kg/min). To facilitate ventilation, muscular
paralysis was achieved with pancuronium bromide (Pan-
curonium™, DeltaSelect, Dreieich, Germany, bolus
injection 0.2 mg/kg after induction of anesthesia, fol-
lowed by continuous infusion of 0.13 mg/kg/min). Esti-
mated fluid losses were replaced with Ringer’ss o l u t i o n
(Ringer-Infusionslösung™, Braun, Melsungen, Germany,
3 mL/kg/h).
Animals were orotracheally intubated and ventilated
with ambient air at a rate of 14 cycles/min and a posi-
tive end-expiratory pressure of 5 cmH2O (Servo 900B,
SiemensElema, Solna, Sweden). Tidal volume was indivi-
dually adjusted to provide arterial normocapnia and was
then maintained throughout the entire protocol.
Instrumentation and monitoring
Animals were placed in the supine position and a five-
lead electrocardiogram (II, V5) was installed for
detection of arrhythmias and ST-segment changes. A
double-lumen catheter (Arrow, Reading, PA, USA) was
inserted into the cranial vena cava and a Swan-Ganz-
Catheter (Baxter, Irvine, CA, USA) was floated into a
branch of the pulmonary artery. Each one 6F introducer
sheath (Arrow, Reading, PA, USA) was inserted into the
right femoral vein and artery, respectively. For continu-
ous measurement of arterial blood pressure and cardiac
output, a thermodilution catheter was placed into the
left femoral artery (Pulsion Medical Systems, Munich,
Germany). Body core temperature was kept constant
using a warming pad.
Experimental protocol
Upon completion of catheter insertion and installation
of the different measuring devices, a 60 min stabilization
period was allowed to elapse before the first data set
was recorded (baseline). Subsequently, animals were
randomized to undergo acute normovolemic hemodilu-
tion with one of the following fluids: 1) 6% HES 130/0.4
(tetrastarch, TS-group, n = 9); 2) 6% HES 450/0.7
(hetastarch, HS-group, n = 9); 3) 3.5% urea-crosslinked
polygeline (gelatin, GEL-group, n =9 ) ,o r4 )R i n g e r ’s
solution (RS-group, n = 9).
Acute normovolemic anemia was induced by withdra-
wal of blood (1mL/kg/min) and simultaneous infusion
of one of the IV fluids. To maintain normovolemia dur-
ing the hemodilution protocol, the following infusion
rates were chosen with regard to the different plasma
expansion effects of the fluids investigated (see Table 1):
Ringer’s solution 3 mL/kg/min, gelatin 1.2 mL/kg/min,
tetrastarch and hetastarch 1 mL/kg/min, respectively.
Infusion fluids were warmed in an immersion bath until
IV infusion. For precise synchronization of blood with-
drawal with the corresponding infusion rates, a bidirec-
tional precision pump (Harvard Apparatus, Holliston,
MA, USA) was used.
The target parameter of the hemodilution protocol
was the animal’s individual critical Hb concentration
(Hbcrit), which was defined as the Hb concentration cor-
responding with a critical limitation of O2 delivery to
the tissues (DO2) and the onset of O2 supply-depen-
dency of total body O2 consumption-VO2 (see below).
At the end of the hemodilution protocol, animals were
killed by intracardiac injection of saturated potassium
chloride solution.
Measurements
Intravascular blood volume was determined at baseline
using the “whole-blood” method of the indocyanin
green (ICG) indicator dilution technique, which has
already been described in detail elsewhere [7]. The pres-
sure transducers of the cardiovascular catheters were
connected with a multi-channel recorder and a personal
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continuous measurement of hemodynamic parameters.
Cardiac output was continuously measured using the
pulse contour analysis (PICCO classic monitor, Pulsion
Medical Systems, Munich, Germany). The volumetric pre-
load and extravasation parameters, intrathoracic blood
volume (ITBV) and extravascular lung water (EVLW),
were assessed after exchange of each 10% of the circulat-
ing blood volume using the transpulmonary thermodilu-
tion technique. Arterial and mixed venous blood samples
were withdrawn at baseline, after exchange of each 10% of
the circulating blood volume and at Hbcrit for blood gas
analysis and assessment of Hb concentration (GEM-3000
and 682 CO-Oxymeter, Instrumentation Laboratory, Lex-
ington, MA, USA).
Calculated parameters
Body surface area (BSA) was calculated according to
Holt [8], from body weight (BW) and a species-depen-
dent constant:
BSA = k · BW
2
3

m2
,
where k = 9 for the species pig.
The measured values of cardiac output (CO) and O2
consumption (VO2) were indexed to BSA:
CI =
CO
BSA

l
min·m2

VO2I =
VO2
BSA

ml
min·m2

Systemic and pulmonary vascular resistance indices
(SVRI and PVRI) were calculated from standard formu-
lae:
SVRI =
(MAP − CVP) · 79.9
CI

dyn · s
cm5 · m2

PVRI =
(MPAP − PCWP) · 79.9
CI

dyn · s
cm5 · m2

where MAP = mean arterial pressure, CVP = central
venous pressure, CI = cardiac index, MPAP = mean pul-
monary arterial pressure and PCWP = pulmonary capil-
lary wedge pressure.
Arterial and mixed venous O2 content (CaO2 and
CvO2), O2 delivery (DO2I) and O2 extraction ratio were
calculated as follows:
CaO2 =

Hb

· 1.34 · SaO2 +0 . 0 0 3 1· paO2

mL
dL

CvO2 =

Hb

· 1.34 · SvO2 +0 . 0 0 3 1· pvO2

mL
dL

DO2I = CI · CaO2

mL
min·m2

O2 − ER =
CaO2 − CvO2
CaO2
(%)
Determination of Hbcrit
Hbcrit is the correlate of the critical limitation of DO2,a n d
marks the onset of total body O2 supply-dependency. The
corresponding decrease of VO2 was prospectively detected
in an automated and investigator-independent manner:
VO2 was measured every 60 sec with a metabolic monitor
(Delta-Trac II™ MBM-200, Datex-Engstrom, Helsinki,
Finland). VO2 values were simultaneously recorded and
computed with specific software (Delta-Crit-System, DCS)
[9]. During the stabilization period, the DCS enters VO2
values into an online regression analysis and calculates the
mean and standard deviation (SD). During the subsequent
hemodilution period, the VO2 value obtained every 60
secis compared to the mean value predicted by the DCS.
Table 1 Characteristics and trade names of intravenous fluids investigated in the present study [25].
Tetrastarch Hetastarch Gelatin Ringer’s solution
Concentration (%) 6 6 3.5 n.a.
Mean molecular
weight (kDa)
130 450 35 n.a.
Volume efficacy (%) 100 100 80 30
Volume effect (min) 120-180 300-360 60-180 20
Viscosity (cp) 2.1 3.9 1.7 n.a.
COP in vitro (mmHg) 36 26 25 n.a.
Trade name Voluven™, Fresenius Kabi, Bad
Homburg, Germany
HESPAN™,
Braun,
Irvine, CA,
USA
Haemaccel™, DeltaSelect,
Dreieich,
Germany
Ringer-Infusions-lösung™, Braun,
Melsungen, Germany
COP, colloidal oncotic pressure; n.a., not applicable.
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fined range (3-fold SD of the regression line), a significant
decrease of VO2 is assumed (see Figure 1) and the compu-
ter alerts visually and acoustically [9]. For determination of
Hbcrit, the corresponding Hb concentration was measured
in the arterial blood sample.
Statistics
Statistical analysis was performed with the SAS 9.1 soft-
ware package (SAS Institute, Cary, NC, USA). All data
are presented as mean ± SD. Distribution of data was
assessed with the Shapiro-Wilk test. In the case of nor-
mal distribution, the time effect on the different variables,
and differences between groups at different time points
were tested by repeated analysis of variance (ANOVA).
Post hoc analysis of differences detected with ANOVA
was performed with the Student Newman Keuls test. In
t h ec a s eo fn o n - n o r m a ld i s t r i b u t i o n ,t h et i m ee f f e c to n
the parameters, and the between-group differences were
tested by analysis of variance on ranks (rANOVA). Post
hoc analysis of differences detected with rANOVA was
performed with Tukey’s test. For all parameters, statisti-
cal significance was accepted at P < 0.05.
Results
Baseline characteristics
On analysis of baseline body weight, blood volume index
and all investigated parameters of hemodynamics and
O2 transport, there were no significant differences
detected between the groups (see Tables 2 and 3).
Primary endpoint: critical Hb concentation (Hbcrit)
Depending on the plasma substitute used for hemodilu-
tion, Hbcrit w a sm e ta t2 . 1±0 . 4g / d L( T S - g r o u p ) ,2 . 7±
0 . 6g / d L( G E L - g r o u p ) ,3 . 0±0 . 6g / d L( H S - g r o u p )a n d
3.7 ± 0.6 g/dL (RS-group). The lowest value of Hbcrit
was attained in the TS-group (P < 0.05 vs. GEL, HS and
RS). While Hbcrit did not differ significantly between the
GEL- and HS-groups, the difference between the RS-
group and the other groups (GEL-, HS- and TS- groups)
was statistically significant (see Figure 2).
The induction of critical normovolemic anemia
required the exchange of 69 ± 21% of the circulating
blood volume (BV) for Ringer’ss o l u t i o n ,7 1±1 9 %B V
for hetastarch, 93 ± 44% BV for gelatin (P <0 . 0 5v s .
HS- and RS-groups) and 107 ± 28% BV for tetrastarch
(P < 0.05 vs. HS- and RS-groups). For maintenance of
normovolemia, animals received 1,812 ± 535 mL tetra-
starch, 2,016 ± 898 mL gelatin, 1,369 ± 324 mL hetas-
tarch (P < 0.05 vs. TS-group), or 3,698 ± 1320 mL
Ringer’s solution, respectively (P < 0.05 vs. TS- GEL-
and HS-groups).
Secondary endpoints: hemodynamic and O2-derived
parameters
In Tables 2 and 3, hemodynamic and O2-derived para-
meters are presented at the respective critical Hb con-
centrations, that is, after hemodilution to 3.7 g/dL, 3.0
g/dL, 2.7 g/dL and 2.1 g/dL, respectively.
Hemodilution to Hb 3.7 g/dL (Hbcrit of the RS-group)
As compensation for hemodilution, cardiac index (CI)
increased by 46 to 60% in all groups (P <0 . 0 5v s .b a s e -
line). Consistently, stroke volume index (SVI) and heart
rate (HR) increased by 24 to 40% and 14 to 18%, respec-
tively. While the increases in SVI were significant in the
TS-group, GEL-, and RS-groups, the increase in HR was
not significant in any group. Mean arterial pressure
(MAP) decreased by 11 to 21% in the GEL-, HS- and
RS-groups (non-significant) and systemic vascular resis-
tance index (SVRI) decreased in all groups by 35 to 46%
(P < 0.05 vs. baseline), while mean pulmonary arterial
pressure (MPAP) increased by 22 to 50% (P <0 . 0 5v s .
baseline in the GEL-, HS and RS-group). Stroke volume
variation (SVV) remained unchanged in the RS-group
and tended to decrease in the TS- and GEL-groups. In
the HS-group, the decrease in SVV was statistically sig-
nificant. Compared with baseline, ITBV index (ITBVI)
increased in all groups (P < 0.05), reflecting increased
venous return to the heart. The ITBVI was higher in
animals hemodiluted with TS or HS than after fluid
replacement with RS (P < 0.05). As a consequence of
hemodilution, DO2I decreased by 14 to 30% in all
groups (P < 0.05 vs. baseline). Moreover, the pH-value
and base excess (BE) decreased significantly in the GEL-
, HS- and RS-groups. As the protocol was terminated at
Figure 1 Typical example of a recording of total body oxygen
consumption (VO2) in the course of the experimental protocol.
A linear regression analysis including the calculation of SD was
performed with VO2 values collected during the 60-minute
stabilization period. During the subsequent hemodilution protocol, a
critical limitation of oxygen delivery (DO2) was assumed, when three
consecutive VO2 values fell below the lower 3s-range.
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Page 4 of 11Table 2 Hemodynamic parameters obtained at baseline and after hemodilution to the individual Hbcrit of the RL-, HS-,
GEL- and TS-groups.
Parameter Group Baseline Hbcrit RS-group Hbcrit HS-group Hbcrit GEL-group Hbcrit TS-group
BVI TS 73 ± 6 n.a. n.a. n.a. n.a.
(ml/kg) GEL 76 ± 9 n.a. n.a. n.a. n.a.
HS 73 ± 3 n.a. n.a. n.a. n.a.
RS 76 ± 8 n.a. n.a. n.a. n.a.
HR TS 102 ± 15 115 ± 19 120 ± 16 132 ± 25 + 133 ± 29 +
(1/min) GEL 100 ± 23 111 ± 16 114 ± 15 126 ± 15 + n.a.
HS 102 ± 19 120 ± 17 121 ± 8 + n.a. n.a.
RS 111 ± 20 127 ± 35 n.a. n.a. n.a.
MAP TS 81 ± 14 88 ± 18 84 ± 18 80 ± 19 59 ± 15
(mmHg) GEL 88 ± 12 78 ± 14 77 ± 15 64 ± 12 + n.a.
HS 88 ± 20 75 ± 13 70 ± 13 + n.a. n.a.
RS 90 ± 20 71 ± 10 n.a. n.a. n.a.
MPAP TS 19 ± 4 23 ± 4 23 ± 4 23 ± 4 23 ± 5
(mmHg) GEL 19 ± 3 25 ± 6 + 24 ± 5 + 26 ± 5 + n.a.
HS 18 ± 3 22 ± 6 + 24 ± 4 + n.a. n.a.
RS 18 ± 3 27 ± 11 + n.a. n.a. n.a.
CI TS 4.2 ± 0.5 6.7 ± 0.8 + 7.5 ± 1.2 + 7.7 ± 1.1 + 8.0 ± 2.8 +
(L/min/m
2) GEL 4.6 ± 0.8 6.7 ± 0.7 + 7.5 ± 0.5 + 7.5 ± 0.9 + n.a.
HS 4.5 ± 0.5 6.7 ± 0.6 + 7.0 ± 1.1 + n.a. n.a.
RS 4.4 ± 0.8 6.7 ± 0.8 + n.a. n.a. n.a.
SVI TS 42 ± 8 59 ± 11 + 63 ± 11 + 59 ± 11 + 57 ± 3 +
(mL/m
2) GEL 47 ± 7 62 ± 12 + 67 ± 10 + 61 ± 9 n.a
HS 45 ± 9 56 ± 7 55 ± 11 n.a n.a
RS 41 ± 9 55 ± 13 + n.a. n.a. n.a.
C V P T S 6±4 7±0 8±3 8±2 8±1
(mmHg)] GEL 5 ± 3 8 ± 3 8 ± 3 8 ± 3 n.a.
HS 6 ± 3 9 ± 4 10 ± 6 n.a. n.a.
RS 4 ± 2 7 ± 3 + n.a. n.a. n.a.
PCWP TS 5 ± 3 7 ± 2 6 ± 2 7 ± 2 8 ± 2
(mmHg) GEL 6 ± 2 6 ± 3 7 ± 3 7 ± 3 n.a.
HS 4 ± 3 5 ± 2 5 ± 3 n.a. n.a.
RS 4 ± 3 6 ± 3 n.a. n.a. n.a.
ITBVI TS 673 ± 65 857 ± 142 +§ 856 ± 63 + 844 ± 78 +* 764 ± 177
(mL/m
2) GEL 699 ± 94 818 ± 101 + 824 ± 82 + 784 ± 57 + n.a.
HS 664 ± 78 829 ± 84 +§ 774 ± 86 + n.a. n.a.
RS 699 ± 34 761 ± 70 + n.a. n.a. n.a.
SVV TS 21 ± 6 13 ± 3 10 ± 3 + 11 ± 3 +* 10 ± 2 +
(%) GEL 19 ± 5 12 ± 3 10 ± 3 + 16 ± 4 n.a.
HS 20 ± 6 14 ± 2 +§ 13 ± 3 + n.a. n.a.
RS 17 ± 1 18 ± 7 n.a. n.a. n.a.
SVRI TS 1447 ± 342 943 ± 178 + 817 ± 212 + 751 ± 204 + 517 ± 126 +
(dyn/sec/cm
5/m
2) GEL 1489 ± 433 834 ± 180 + 736 ± 181 + 603 ± 147 + n.a.
HS 1490 ± 386 801 ± 236 + 590 ± 135 + n.a. n.a.
RS 1578 ± 439 871 ± 221 + n.a. n.a. n.a.
BVI, blood volume indexed to body weight (only assessed at baseline); HR, heart rate; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; CI,
cardiac index; SVI, stroke volume index; CVP, central venous pressure; PCWP, pulmonary capillary wedge pressure; ITBVI, intrathoracic blood volume index; SVV,
stroke volume variation; SVRI, systemic vascular resistance index; n.a., not applicable. *P < 0.05 vs. gelatin, # P < 0.05 vs. HS, § P < 0.05 vs. RS, +P < 0.05 vs.
baseline.
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Page 5 of 11Table 3 Oxygen-derived parameters investigated at baseline and after hemodilution to the individual Hbcrit of the RL-,
HS-, GEL- and TS-groups.
Parameter Group Baseline Hbcrit RS-group Hbcrit HS-group Hbcrit GEL-group Hbcrit TS-group
Hb TS 7.6 ± 0.6 3.7 ± 0.2 + 3.0 ± 0.1 + 2.7 ± 0.1 + 2.1 ± 0.4 +
(g/dL) GEL 7.7 ± 0.5 3.6 ± 0.3 + 2.9 ± 0.2 + 2.7 ± 0.7 + n.a.
HS 7.6 ± 0.4 3.7 ± 0.3 + 3.0 ± 0.6 + n.a. n.a.
RS 7.9 ± 0.5 3.7 ± 0.6 + n.a. n.a. n.a.
Temp. TS 37.8 ± 1.3 37.5 ± 0.5 37.6 ± 0.4 37.7 ± 1.2 37.6 ± 1.2
(°C) GEL 37.5 ± 1.0 37.4 ± 1.2 37.3 ± 0.8 37.2 ± 1.0 n.a.
HS 37.6 ± 1.1 37.6 ± 1.0 37.4 ± 1.2 n.a. n.a.
RS 37.7 ± 0.7 37.4 ± 0.6 n.a. n.a. n.a.
paO2 TS 94 ± 9 95 ± 12 § 100 ± 13 98 ± 14 105 ± 22
(mmHg) GEL 98 ± 10 99 ± 19 § 101 ± 14 95 ± 18 n.a.
HS 95 ± 7 98 ± 9 § 101 ± 11 n.a. n.a.
RS 100 ± 8 79 ± 10 + n.a. n.a. n.a.
paCO2 TS 34 ± 3 35 ± 4 34 ± 4 34 ± 4 33 ± 4
(mmHg) GEL 34 ± 2 35 ± 3 34 ± 4 35 ± 4 n.a.
HS 33 ± 4 33 ± 3 33 ± 3 n.a. n.a.
RS 32 ± 3 32 ± 4 n.a. n.a. n.a.
pvO2 TS 34 ± 3 31 ± 5 32 ± 4 31 ± 4 29 ± 4 +
(mmHg) GEL 34 ± 2 32 ± 3 34 ± 2 # 32 ± 4 n.a.
HS 33 ± 4 35 ± 4 29 ± 3 + n.a. n.a.
RS 32 ± 3 34 ± 3 n.a. n.a. n.a.
DO2I TS 428 ± 45 367 ± 58 + 324 ± 54 + 287 ± 20 + 253 ± 84 +
(mL/min/m
2) GEL 478 ± 67 348 ± 51 + 328 ± 35 + 289 ± 44 + n.a.
HS 455 ± 53 353 ± 22 + 303 ± 65 + n.a. n.a.
RS 487 ± 109 339 ± 69 + n.a. n.a. n.a.
VO2I TS 223 ± 33 219 ± 29 203 ± 14 216 ± 34 199 ± 35
(mL/min/m
2) GEL 219 ± 17 210 ± 10 201 ± 12 199 ± 12 n.a.
HS 229 ± 37 199 ± 10 211 ± 35 n.a. n.a.
RS 222 ± 23 203 ± 26 n.a. n.a. n.a.
O2-ER TS 37 ± 5 46 ± 11 45 ± 7 # 46 ± 11 52 ± 13 +
(%) GEL 35 ± 5 46 ± 8 41 ± 7 # 45 ± 12 + n.a.
HS 38 ± 9 44 ± 6 52 ± 9 + n.a. n.a.
RS 39 ± 7 44 ± 6 n.a. n.a. n.a.
pH TS 7.57 ± 0.04 7.53 ± 0.04 7.52 ± 0.04 7.51 ± 0.04 7.50 ± 0.06
GEL 7.58 ± 0.02 7.50 ± 0.03 + 7.49 ± 0.03 7.47 ± 0.04 n.a.
HS 7.59 ± 0.04 7.55 ± 0.05 + 7.53 ± 0.04 n.a. n.a.
RS 7.58 ± 0.05 7.42 ± 0.08 + n.a. n.a. n.a.
BE TS 8.7 ± 3.4 6.1 ± 3.5 § 5.0 ± 3.4 4.2 ± 3.4 + 2.4 ± 4.0 +
(mmol/L) GEL 9.4 ± 2.0 4.0 ± 1.7 +§ 2.7 ± 2.1 + 1.8 ± 2.8 + n.a.
HS 9.3 ± 2.4 6.2 ± 3.0 +§ 4.6 ± 2.5 + n.a. n.a.
RS 7.5 ± 2.1 -3.5 ± 3.4 + n.a. n.a. n.a.
Lactate TS 1.9 ± 0.9 1.7 ± 0.8 1.7 ± 0.8 1.7 ± 0.9 2.3 ± 1.0
(mmol/L) GEL 1.4 ± 0.3 1.2 ± 0.3 1.1 ± 0.3 1.1 ± 0.3 n.a.
HS 1.7 ± 0.7 1.6 ± 0.5 1.8 ± 0.1 n.a. n.a.
RS 1.4 ± 0.6 1.3 ± 0.6 n.a. n.a. n.a.
Temp, body core temperature; Hb, haemoglobin concentration; paO2, arterial O2 partial pressure; pvO2, mixed venous O2 partial pressure; paCO2, arterial CO2
partial pressure; VO2I and DO2I, indices of O2 consumption and delivery; O2-ER, O2 extraction ratio; pH, pH value; BE, base excess; lactate, lactate concentration; n.
a., not applicable. *P < 0.05 vs. gelatin, #P < 0.05 vs. HS, §P < 0.05 vs. RS, +P < 0.05 vs. baseline.
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Page 6 of 11the onset of the critical DO2, lactate concentration was
not yet elevated at this time point (see Table 3). The
EVLW index (EVLWI) was significantly increased in the
RS-group (P < 0.05 vs. baseline and P < 0.05 vs. GEL-,
H S -a n dT S - g r o u p s ,s e eF i g u r e3 ). Consistently, arterial
oxygen partial pressure (paO2) was decreased in the
RS-group (P < 0.05 vs. baseline and P < 0.05 vs. GEL-,
HS- and TS-groups).
Hemodilution to Hb 3.0 g/dL (Hbcrit of the HS-group)
As the limit of anemia tolerance was already met at Hb
3.7 g/dL in the RS-group, hemodilution to 3.0 g/dL could
only be performed in the HS-, GEL- and TS-groups.
A slight increase in CI, HR and SVI and a decrease in
MAP and SVRI was observed in these groups, and SVV
was significantly reduced compared with baseline. The
ITBVI did not change further, but remained elevated
above the baseline level (P < 0.05). There were no differ-
ences between the HS-, GEL and TS-groups in hemody-
namic parameters at Hb 3.0 g/dL.
Consistent with progressive hemodilution, DO2I
further decreased in the remaining HS-, GEL- and TS-
groups. In animals hemodiluted with hetastarch, O2
extraction was significantly increased as reflected by
lower partial venous oxygen pressure (pvO2)( P <0 . 0 5
vs. baseline and vs. GEL-group) and by a higher O2
extraction ratio (P < 0.05 vs. baseline and vs. GEL- and
TS-groups).
Hemodilution to Hb 2.7 g/dL (that is, Hbcrit of the GEL-
group)
Hemodilution could be continued to Hb 2.7 g/dL in the
GEL- and TS-groups. CI did not increase further, but
was now maintained by an elevation of HR in both
groups (P < 0.05 vs. baseline). The MAP and SVRI
decreased slightly (non-significant vs. baseline). In both
groups, the ITBVI was still higher than at baseline (P <
0.05). However, at Hb 2.7 g/dL, the ITBVI was higher
and SVV was lower in the TS-group (P <0 . 0 5v s .G E L -
group). In the GEL-group, the O2 extraction ratio (O2-
ER) and EVLWI were elevated when compared with
baseline (P <0 . 0 5 ,s e eF i g u r e3 ) .N of u r t h e rd i f f e r e n c e s
between the TS- and GEL-groups were observed in
hemodynamic or O2-derived parameters at Hb 2.7 g/dL.
Hemodilution to Hb 2.1 g/dL (Hbcrit of the TS-group)
Hemodilution could be performed most extensively with
tetrastarch. When animals of the TS-group met their
individual Hbcrit at 2.1 g/dL, the following changes
were significantly different to baseline: HR, CI, SVI and
EVLWI increased by 30%, 90%, 36% and 38%, while
SVV, SVRI, DO2I, pvO2 and BE decreased by 52%, 64%,
40%, 15% and 72%, respectively (P <0 . 0 5 ) .M o r e o v e r ,
O2-ER increased by 38% and by 40% (see Table 3).
Discussion
The main findings of the present study are that during
acute normovolemic anemia, 1) the choice of the IV
fluid has an impact on the maintenance of tissue
Figure 2 Critical hemoglobin concentration (crit obtained after
induction of acute anemia. Anemia was induced using tetrastarch
(TS-group, Hbcrit 2.1 ± 0.4 g/dL), gelatin (GEL-group, Hbcrit 2.7 ± 0.6
g/dL), hetastarch (HS-group, Hbcrit 3.0 ± 0.6 g/dL) or Ringer’s
solution (RS-group, Hbcrit 3.7 ± 0.6 g/dL). *P < 0.05 vs. GEL, #P <
0.05 vs. HS, §P < 0.05 vs. RS. Figure 3 Extravascular lung water index (EVLWI) obtained at
baseline after hemodilution to Hb 3.7 g/dL (Hbcrit of the RS-
group), Hb 3.0 g/dL (Hbcrit of the HS-group), Hb 2.7 (Hbcrit of the
GEL-group) and Hb 2.1 (Hbcrit of the TS-group). At Hb 3.7 g/dL,
EVLWI was significantly higher in the RS-group than in the TS-, GEL-,
and HS-groups. *P < 0.05 vs. GEL, #P < 0.05 vs. HS, §P < 0.05 vs. RS,
+P < 0.05 vs. baseline. Hbcrit, critical haemoglobin concentration,
error bars represent standard deviation of mean.
Pape et al. Critical Care 2012, 16:R69
http://ccforum.com/content/16/2/R69
Page 7 of 11oxygenation as reflected by variation in the extent of
anemia tolerance; 2) anemia tolerance is higher when
using colloids than when using crystalloids, and 3)
among the colloids, tetrastarch (6% HES 130/0.4) pro-
vided higher anemia tolerance than did gelatin (3.5%
urea-crosslinked polygeline) and hetastarch (6% HES
450/0.7). This was reflected by significantly lower values
of Hbcrit and a higher allowable volume of blood
exchanged for tetrastarch.
Hbcrit is the hemoglobin concentration associated with
a critical limitation of O2 supply and hallmarks the ulti-
mate tolerance limit of acute normovolemic anemia
[10,11]. In our previous experimental studies, hemodilu-
tion to Hbcrit was associated with 100% mortality, if no
further treatment (such as elevation of fraction of
inspired O2, transfusion of red blood cells, or infusion
of artificial O2 carriers) was initiated after institution of
critical normovolemic anemia [12-14]. Several authors
found Hbcrit at values between 1.6 and 3.0 g/dL
[10,12,14-21]. In detail, Hbcrit was reduced by 1)
hypothermia (moderate reduction of body core tempera-
ture reduces total body O2 demand [15]); 2) hyperoxe-
mia (bioavailability of physically dissolved O2 is
excellent in profound anemia [12,16,17]); 3) infusion of
norepinephrine (stabilization of coronary perfusion pres-
sure during hemodilution [19]); 4) artificial O2 carriers
(maintenance of arterial oxygen content despite reduced
hematocrit [18,22]), and 5) con-tinuous neuromuscular
blockade (lowering skeletal muscular O2 demand [23]).
While different infusion fluids were used for hemodi-
lution in the aforementioned studies, their particular
impact on the limit of anemia tolerance has not been
fully elucidated. In a similar hemodilution study per-
formed in anesthetized and splenectomised dogs, van
der Linden and coworkers found no differences between
pentastarch (6% HES 200/0.5) and a 3% gelatin prepara-
tion in relation to the value of Hbcrit [20]. However, the
typical increase of CI in compensation for dilutional
anemia was absent in that study, which was explained
by cardio-depressant effects of the anesthesia regimen
employed [20,21].
In the present study, gelatin provided more extensive
anemia tolerance than did hetastarch. While the occa-
sional use of hetastarch is predominantly reported by
US physicians [24], European physicians rather avoid
this fluid due to its adverse effects on coagulation and
renal function [25]. Nevertheless, a recent clinical study
found a reduction of mortality in trauma victims resus-
citated with hetastarch in addition to the advanced
trauma life support (ATLS)-standard of care treatment
(that is, crystalloids along with blood products) [26].
Hetastarch is a hyperoncotic infusion fluid with a high
viscosity in vitro (see Table 1). However, the effects of
these properties in vivo are still not fully understood.
While a decrease of plasma viscosity entails the increase
of venous return, thereby enabling the hemodynamic
compensation of acute anemia [27], recent experimental
data suggest that increased plasma viscosity prevents
microvascular collapse (for example, after fluid resusci-
tation from hemorrhagic shock) [6]. Furthermore, the
effect of hetastarch on plasma viscosity is limited by its
oncotic properties, as the reabsorption of interstitial
fluid involves the dilution of viscogenic materials
thereby lowering plasma viscosity in the long term [28].
In the present study, animals hemodiluted with hetas-
tarch featured a significantly higher O2-ER at Hbcrit
when compared with animals of the TS- or GEL-group,
indicating that macro- and microhemodynamic compen-
sation of anemia was completely exhausted. In other
words, hetastarch failed to prevent microcirculatory col-
lapse at an earlier stage of hemodilution than did tetra-
starch or gelatin. Although plasma viscosity was not
assessed in the present study, it may be assumed that a
dilution-related fading of viscogenic potential might
have contributed to this result.
Whether fluid resuscitation should be performed with
crystalloids or colloids, has been a matter of controversy
for decades, and the discussion is still open [29].
Although most crystalloid infusion fluids are plasma-iso-
tonic, they cross the capillary membranes within 20 to
30 minutes of infusion, and most of the volume infused
is shifted into the interstitium. To maintain normovole-
mia with crystalloids, it has been recom-mended to
replace an acute blood loss in a ratio of at least 1:3 [30].
However, the exclusive use of crystalloids for volume
replacement results in edema formation and may
thereby compromise tissue oxygenation [31]. Actually,
excessive tissue hydration due to pure crystalloid
volume replacement in the perioperative phase was held
responsible for many postoperative complications
including increased incidence of anastomotic dehiscence
in abdominal surgery, postoperative vomiting and ortho-
static dysregulation [32,33]. Moreover, an experimental
study in pigs subjected to colon anastomosis surgery
found that microcirculatory blood flow and oxygen ten-
sion in perianastomotic colon tissue were increased in
animals infused with tetrastarch when compared with
crystalloid fluid management [34]. This finding was
explained by homogenisation of mucosal microcircula-
tory blood flow after infusion of tetrastarch.
In the present study, with Ringer’ss o l u t i o n ,t h e
exchange of blood was associated with increased pul-
monary edema formation (elevated EVLWI) and an
impairment of pulmonary gas exchange (decreased
paO2). This phenomenon was not observed in animals
hemodiluted with gelatin, hetastarch or tetrastarch.
Although EVLWI merely reflects the degree of tissue
hydration at the site of pulmonary circulation, it may be
Pape et al. Critical Care 2012, 16:R69
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in peripheral O2-consuming tissues: while O2 extraction
increased consistently in animals hemodiluted with any
of these colloids, O2 extraction was not increased when
animals of the RS-group met their individual Hbcrit.A s
this finding may reflect a microcirculatory disorder
related to excessive tissue hydration, we conclude that
the comparatively early VO2-decrease in the RS-group
might, in addition to the anemia-related restriction of
the O2 transport capacity, also be attributable to an
edema-related impairment of O2 uptake at the site of
pulmonary and peripheral microcirculation.
A certain transcapillary filtration rate is also character-
istic for gelatin preparations [35]. Their low molecular
weight (30 to 40 kDa) entails a rapid passage into the
interstitial space and a rapid clearance by glomerular fil-
tration, finally reducing volume efficacy to 80% (that is,
20% extravasation rate). Consistently, EVLWI increased
much later in the GEL-group than in the RS-group.
Moreover, when hemodilution was continued below Hb
3.7 g/dL, O2 extraction could be augmented, reflecting
that microcirculatory function might have been main-
tained more adequately than in the RS-group.
The strict maintenance of normovolemia is essential for
adequate hemodynamic compensation of acute anemia,
that is, for the increase in cardiac output. However, one
weakness of the present protocol is the verification of nor-
movolemia at time points characterized by extreme ane-
mia. During extreme hemodilution, the kinetic of ICG
elimination is significantly altered by dilution of albumin
and increased cardiac output. Therefore, a measurement
of circulating blood volume at this point would yield
results not comparable with the baseline measurement [7],
so normovolemia was deduced from clinically assessable
parameters, for example, ITBVI and SVV.
While ITBVI represents LV preload, decreases in SVV
reflect adequate volume responsiveness. After hemodilu-
tion with either fluid, ITBVI increased above the baseline
level, indicating that volume replacement was adequate to
achieve macro-hemodynamic compensation of acute ane-
mia (increase of venous return to the heart, augmentation
of LV preload). However, the increase of ITBVI was more
pronounced in the TS- and HS-groups. In the course of
hemodilution, SVV decreased in the TS-, GEL-, and HS-
groups. In the RS-group, SVV remained unchanged and at
Hbcrit, it was significantly lower than in the HS-group.
Both findings reflect that volume responsiveness was most
strongly expressed in the starch groups. In the RS-group,
however, volume responsiveness and volume efficacy were
limited by partial extravasation despite infusion of 3 mL
RS per mL blood withdrawn.
Although this procedure provided adequate LV pre-
load for hemodynamic compensation of acute anemia, it
may be argued that the infusion of higher volumes of
RS (4 or 5 mL per mL blood withdrawn) might have
elevated intravascular volume and might have improved
volume responsiveness. On the other hand, extravasa-
tion and tissue hydration would have exacerbated and
might have further impaired O2 uptake and tissue
oxygenation.
Likewise, the volume effect of gelatin appeared to be
limited by its short intravascular half-life and its extrava-
sation tendency. No differences between the colloid
groups were observed in LV preload or volume respon-
siveness until hemodilution to Hb 3.0 g/dL. However,
after continuation of hemodilution to 2.7 g/dL, ITBVI
tended to decrease and SVV to increase in the GEL-
group, and both parameters differed significantly from
the TS-group. Nevertheless, animals of the GEL-group
still featured sufficient hemodynamic compensation of
acute anemia (CI, SVI and ITBVI remained increased vs.
baseline), which precludes that they were actually
hypovolemic.
These findings indicate that 1) the infusion of 1.2 mL
gelatin per mL blood withdrawn was adequate to main-
tain LV preload and volume responsiveness over a wide
range of the hemodilution protocol; 2) in spite of this,
the volume effect of gelatin could not be sustained until
the end of the protocol, and 3) that extravasation and
fading volume responsiveness might have compromised
microvascular perfusion, which finally caused animals of
the GEL-group to earlier achieve Hbcrit than the TS-
group.
We chose Hbcrit as the primary endpoint of the hemo-
dilution protocol. In our previous studies, lactate con-
centrations began to increase 60 to 90 minutes after
institution of Hbcrit [12-14,19]. Of note, we employed
the identical hemodilution protocol in the present study
but animals were killed immediately after achievement
of Hbcrit, so that elevated lactate concentrations could
not yet be expected.
In the present experimental model, the effects of the
investigated infusion fluids became apparent when the
O2 transport capacity was driven to its critical limit.
Whether differences between the groups existed already
at less severe degrees of anemia, is difficult to conclude.
However, a clinical investigation in healthy volunteers
undergoing moderate hemodilution with different HES
preparations (HES 130/0.4, HES 70/0.5 or HES 200/0.5)
demonstrated that tetrastarch provided the most sus-
tained increase of tissue O2 partial pressure (tpO2) [36].
In summary, our data suggest that the choice of the
IV infusion fluid used for acellular volume replacement
has an impact on the maintenance of O2 supply. Among
the fluids investigated in the present study, tetrastarch
(HES 130/0.4) provided the most extensive anemia tol-
erance when compared with gelatin, hetastarch or Ring-
er’s solution. While the exact underlying mechanism
Pape et al. Critical Care 2012, 16:R69
http://ccforum.com/content/16/2/R69
Page 9 of 11remains to be elucidated, extravasation and formation of
interstitial edema were associated with decreased anemia
tolerance, indicating that the microcirculatory effects of
the fluids investigated had a major impact on tissue
oxygenation.
Conclusions
During acellular treatment of an acute blood loss in lieu of
allogeneic blood transfusions (for example, correction of
hypovolemia, bridging an unexpected massive blood loss,
or declining of transfusion for religious reasons), modern
low-molecular tetrastarch preparations (such as HES 130/
0.4) appear most suitable to maintain O2 supply over a
wide range of levels of acute normovolemic anemia.
Key messages
￿ The correction of hypovolemia with acellular fluids
implies the dilution of the cell mass remaining in
the vasculature (acute normovolemic anemia).
￿ Sustainment of normovolemia and nutritive micro-
circulatory blood flow has a major impact on the
maintenance of tissue oxygenation and thereby on
the tolerance of acute anemia.
￿ The fluids investigated in the present study (tetra-
starch, gelatin, hetastarch and Ringer’s Solution) dif-
fered in their volume effects and their extravasation
rate and might thereby have influenced microcircula-
tory function.
￿ In profound anemia, modern low-molecular tetra-
starch preparations were most advantageous to
maintain normovolemia as well as tissue
oxygenation.
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